CEA was first described in 1965 as a serum biomarker in mucinous colon cancer and as a marker in women with ovarian cancer [16,17]; however, in 1981, CA-125 was identified in ovarian, cervical, endometrial, gastrointestinal, and breast cancers [18]. This evidence concerns the gene CEACAM5 and breast carcinoma.